Gain Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
GANX Nasdaq 2836 gaintherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Gain Therapeutics, Inc.

Gain Therapeutics to Present at Neuroscience 2025 - Oct 30th, 2025 5:00 am
Gain Therapeutics to Attend the 2025 Maxim Growth Summit - Oct 16th, 2025 5:00 am
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease - Oct 9th, 2025 5:00 am
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders® - Oct 6th, 2025 6:15 am
Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025 - Sep 23rd, 2025 5:40 am
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease - Sep 18th, 2025 5:41 am
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation - Sep 4th, 2025 6:00 am
Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update - Aug 12th, 2025 5:00 am
Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference - Jul 24th, 2025 6:53 am
Gain Therapeutics Announces Pricing of $7.0 Million Public Offering - Jul 16th, 2025 7:03 am
Gain Therapeutics Announces Proposed Public Offering - Jul 15th, 2025 2:36 pm
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation - Jun 30th, 2025 2:05 pm
Gain Therapeutics to Participate in Upcoming Investor Conferences - Jun 10th, 2025 6:00 am
Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting - May 29th, 2025 6:45 am
Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update - May 14th, 2025 5:30 am
Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - May 12th, 2025 5:30 am
Gain Therapeutics to Participate at The Citizens Life Sciences Conference - May 1st, 2025 5:30 am
Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders - Apr 30th, 2025 5:45 am
Is Gain Therapeutics (GANX) the Top Healthcare Stock to Buy According to Billionaire David Einhorn? - Apr 11th, 2025 12:59 pm
Gain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update - Apr 10th, 2025 5:00 am